HBIO vs XPER

For growth investors, Harvard Bioscience, Inc.

(HBIO) is the stronger pick with -8. 1% revenue growth year-over-year, versus -9. 2% for Xperi Inc. (XPER). Analysts rate Harvard Bioscience, Inc. (HBIO) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Xperi Inc.

(XPER) delivered a total return of -61. 5%, compared to -90. 7% for Harvard Bioscience, Inc. (HBIO). Over 10 years, the gap is even starker: XPER returned -15. 7% versus HBIO's -76. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Xperi Inc.

(XPER) is the lower-risk stock at 1. 52β versus Harvard Bioscience, Inc. 's 2. 03β — meaning HBIO is approximately 34% more volatile than XPER relative to the S&P 500. On balance sheet safety, Xperi Inc. (XPER) carries a lower debt/equity ratio of 6% versus 3% for Harvard Bioscience, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Harvard Bioscience, Inc.

(HBIO) is pulling ahead at -8. 1% versus -9. 2% for Xperi Inc. (XPER). On earnings-per-share growth, the picture is similar: Xperi Inc. grew EPS -296. 8% year-over-year, compared to -357. 1% for Harvard Bioscience, Inc.. Over a 3-year CAGR, XPER leads at -3. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Xperi Inc.

(XPER) is the more profitable company, earning -12. 6% net margin versus -65. 5% for Harvard Bioscience, Inc. — meaning it keeps -12. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HBIO leads at -0. 7% versus -9. 8% for XPER. At the gross margin level — before operating expenses — XPER leads at 71. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, XPER (2.

5% yield) pays a dividend. HBIO does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Xperi Inc.

(XPER) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (2. 5% yield). Harvard Bioscience, Inc. (HBIO) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (XPER: -15. 7%, HBIO: -76. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HBIO (Healthcare) and XPER (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

XPER pays a dividend while HBIO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.